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SUMMARY
The most useful drugs in the management of nephrotic syndrome are the
corticosteroids. These drugs are as well known for their adverse effects
as they are for their therapeutic advantages. The two most common
paediatric side effects are suppression of linear growth and posterior
subcapsular cataracts. Both of these untoward effects are insiduous
and therefore less easily perceived.
Although many workers have studied the growth inhibiting effects of the
corticosteroids in the various diseases e.g. asthma, very little work
was done to investigate these effects in patients with nephrotic syndrome.
Furthermore, the Renal Clinic, King Edward VIII Hospital, Durban continues
to use a daily regime of prednisone instead of the alternate day regime
which is widely recommended to minimise growth retardation. This study
was therefore undertaken to investigate the growth inhibiting effects of
repeated courses of daily, high-dose prednisone in African and Indian
children with nephrotic syndrome.
All children with nephrotic syndrome with relevant data in their
records and with no other chronic illness were selected from the Renal
Clinic. Of the 125 selected, 87 children had been treated with prednisone
for an average of 35,9 weeks and 38 had been treated symptomatically.
The heights of those that received prednisone were measured at an averace
of 77 weeks after completion of therapy. The mean height standard
deviation score (SDS) of the treatment and control groups of Indian
children were -1,06 and -0,92 respectively, both being between the 10th
and 25th percentile, whilst the mean height SDS of the treatment and
control groups of African children were -1,82 (just below the 5th
percentile) and -1,77 (between the 5th and 10th percentile) respectively.
From the results, it is evident that repeated courses of daily prednisone
therapy, even when it exceeds 36 weeks, does not inhibit growth in both
African and Indian children.
Although there was no significant difference between the races and sexes
with respect to growth and corticosteroid therapy, this study does confirm
earlier reports that most of the African children with nephrotic syndrome
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Certain steroid compounds produced by the adrenal cortex have
anti-inflammatory properties and are referred to as
glucocorticosteroids. These compounds are also known as
glucocorticoids, corticosteroids, or for brevity as just
"steroids". In the liver, they have anabolic effects,
increasing production of protein, ribo-nucleic acid (RNA) and
glucose. They also stimulate hepatic glycogenesis and
gluconeogenesis. In peripheral tissues, however, they cause
increased degradation and decreased synthesis of protein, fat,
ribo-nucleic acid (RNA) and deoxyribo-nucleic acid (DNA); and
decreased uptake of glucose and amino acids. Both the anabolic
and catabolic action of these hormones increases total serum
glucose concentration. In addition to these effects on
carbohydrate metabolism, the glucocorticoids play an important
role in the functions of all other body systems. Pharmacological
doses of glucocorticoids retard or interrupt the growth of
children
(18)
. This inhibition of growth is a rather widespread
effect of the glucocorticoids. They, for example, inhibit cell
division or DNA synthesis in thymocytes; fibroblasts; normal,
developing or regenerating liver; gastric mucosa; developing
brain; developing lung and epiderms
(18)
. Nevertheless, this
growth inhibiting effect is selective; therefore the
corticosteroids do not produce the bone marrow depression and
other effects of antimitotic agents.
The only naturally occurring corticosteroids are hydrocortisone
(cortisol) and corticosterone. Structurally, they resemble other
steroids as they share the four-ring carbon skeleton which is
common to these compounds. The structure of hydrocortisone is
shown in Fig. 1. The introduction of a double bond between C 1
and C
2 
converts hydrocortisone into a new compound - prednisone -
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Figure 1. The Structure Of The Hydrocortisone Molecule.
Those parts essential for glucocorticosteroid
activity are encircled. Alterations that enhance
the biologic activity of the molecule are shown
with dotted lines.
3.
There are many synthetic steroid preparations with differing
degrees of potency available for use by the Paediatrician.
These may be given orally, intramuscularly or intravenously.
Oral absorption is generally good and this route of administration
is preferred in most cases. The most common conditions for
which steroid therapy may be indicated are those that are, or
are thought to be immunologically mediated e.g. nephrotic
syndrome, systemic lupus erythematosus and the allergic diseases
e.g. asthma, allergic rhinitis and atopic dermatitis. Table I
lists the conditions in which the corticosteroids have been
used. While their proper use adds greatly to the quality of
life, their misuse can have catastrophic consequences.
1.1.1 Growth Inhibition
The clinical complications of steroid therapy are as
protean as the many therapeutic indications for which
their use has been suggested. These complications have
been listed in Table II. The most common adverse effects
of corticosteroids are cushingoid features (obesity,
moon facies, striae, acne and hirsutism) and growth
suppression. The growth of children is of paramount
importance to parents because they realise that poor
growth may inicate disease and to be unusually short or
tall may have social disadvantages. Most of the literature
emphasizes that daily corticosteroid administration is
associated with a reduction in linear growth. Growth
failure in patients who receive daily prednisone may
result from partial growth hormone deficiency and/or




steroids may suppress growth by direct action on cell
metabolism and/or by effects on Calcium and Phosphorus
metabolism. The two actions of steroids that appear to
be most important in growth suppression are inhibition of
sulphate incorporation into cartilage and inhibition of
generation of somatomedin A
(15)
. Hence skeletal maturation
is also retarded - see Table III.
4.









Anaemia (autoimmune haemolytic and aplastic)
Idiopathic thrombocytopenic purpura







































































Table III. The Mechanisms By Which Corticosteroid Therapy May Cause
Growth Suppression in Children.
1. Partial growth hormone deficiency.
2. Transient decreases in somatomedin levels.
3. Inhibition of cell division or DNA synthesis.
4. Interference with calcium and phosphorus metabolism.
5. Inhibition of sulphate incorporation into cartilage.
6. Excess protein catabolism.
7.
Many workers have shown that the effect of corticosteroids
on growth is not reversed when growth hormone is given
(3)
Tanner et al (1971)
(33)
 reported the use of human growth
hormone in two children with rheumatoid arthritis who were
receiving steroids. In the first case, there was no
response, even to 60 i.u./week, while on a steroid dose
equivalent to 50 mg cortisone daily. In the second case,
a growth spurt occurred while the patient was still
receiving prednisone 3 mg/day, but as she entered puberty
at the same time the significance is obscure. Morris et
al
(26) 
reported that there was marked impairment of the
action of growth hormone in eight steroid-treated
children as compared to non-steroid-treated children.
These observations are in good agreement with the
experience of Preece
(31)
1.1.2 Therapeutic Recommendations 
To minimize the possibility of the undesirable sequelae
while maintaining the therapeutic benefits of corticosteroid
therapy, various recommendations have been made, as listed
in Table IV. Of these, the most important is the
frequency of dosage : specifically, on alternate-day
rather than a daily regime. This approach has been used
in all applications of systemic steroids for nearly
twenty years, and its value has been widely proved
(15)
The rationale for this regime is based upon the fact
that many steroid side effects (especially growth
inhibition) result from the drugs' interference with the
normal function of the hypothalamic - pituitary -
adrenal (HPA) axis. The tissue effects of the short-
acting-steroids cease after about 36 hours, thus the HPA
axis has a 12-hour interval to "recover" before being
again subjected to the next dose of steroid. The two
steroid actions that appear to be most important in
growth suppression (vide supra) are lessened with use of
an alternate-day regime. This supports the work of
8.
Table IV. Recommendations For Corticosteroid Therapy.
1. Use only when no other treatment is effective.
2. Change to an alternate day regimen as soon as possible.
3. Give the drug in a single dose early in the morning.
4. Give as low a dose as possible.




who documented that in children with
kidney disease, alternate-day therapy causes less growth
suppression than does daily therapy; they also showed
that in experimental animals and children with asthma
alternate-day therapy has been associated with normal
growth. Clark & Fitzgerald
(9) 
have shown that an
alternate-day regime has a positive effect on growth,
presumably through control of the underlying disease.
Although catch-up growth may occur after cessation of
daily steroid therapy this is not always the case
especially when therapy has been prolonged for more than
six months
(20)
 . Another important recommendation is
that the drugs should be administered early in the
morning - 7 or 8 o'clock. This is because of the
body's circadian rhythm governing the secretion of
endogenous cortisol. Secretion begins in the early
morning, triggered by the secretion of ACTH which starts
about 1 or 2 am, peaks about 6 am and drops off during
the afternoon and evening to low levels. By synchronizing
the administration of exogenous steroids with the natural
cycle, the tissues are exposed to these potent agents
only at the 'normal' time of day. Also, small amounts of
the drug given at night cause suppression, while the
same dose given in the morning does not
(32)
It is also necessary to emphasize that some of the basic
underlying diseases being treated with corticosteroids
e.g. asthma and nephrosis are themselves associated with
growth retardation. Friedman
(17)
 stated that the most
important causes of growth failure in patients with
chronic renal disease are osteodystroohy, protein -
calorie malnutrition, and chronic glucocorticoid
administration. He added that altered growth hormone
production, metabolism or peripheral utilisation and
acidosis may also be causally related to growth failure.
1 0.
The growth suppressing effects of steroid therapy have
already been examined in various diseases e.g. chronic




chronic arthritis (6, and in children who have had
renal transplants 
(4)
 but little work has been done on the
nephrotic syndrome which is a relatively common condition
for which corticosteroid therapy is used. A recent study
on height attainment in Caucasian children with steroid
responsive nephrotic syndrome has been published
(16)
No similar study has been undertaken among children in
the third world. This project was therefore initiated
to determine the effect of steroid therapy on linear
growth in children with nephrotic syndrome.
1.2 The Nephrotic Syndrome 
This is a clinical term and may be defined as massive
proteinuria (more than 2 Gm/m
2
/24 hrs); hypoalbuminaemia
(430 Gm/L), oedema and hyperlipaemia. It is merely a manifestation
of a large number of morphologically distinct glomerular
disorders which results from primary glomerular disease in
approximately 90% of children. In the remaining 10%, the
nephrotic syndrome is secondary to systemic disease. The causes
of nephrotic syndrome in children are listed in Table V. The
common factor in all these conditions is an abnormally raised
permeability of the glomerular capillary for protein.
This condition was recognised as early as 1853 by Samuel Wilks.
The teim "Nephrosis" was first used by Friedrich Muller in 1905.
It was observed that nephrotic syndrome may improve or disappear
after an intercurrent infection e.g. measles or mumps (Vanucura,
1943), erysipelas (Schwartzer and Kreyher, 1941), typhoid fever
and even appendicitis (Scheiner, 1929). It was therefore
recommended that infection of these patients with measles
(Blumberg and Cassady, 1947); malaria (Gairdner and Shute,
1955) or treatment with non-specific pyrogens such as typhoid
vaccine (Schwartzer and Kreyher, 1941) would be useful. When
it became known that the adrenocortical hormones decrease
11.
Table V. Causes of Nephrotic Syndrome in Children.










Infections - syphilis, malaria, Hepatitis B virus infection
Toxins - mercurials, bismuth, gold, trimethadione, probenicid,
renographic medium, penicillamine
Allergies - poison oak, bee sting, serum sickness, inhaled
pollens, food allergy
Cardiovascular - sickle cell disease, renal vein thrombosis,
passive congestive heart failure
Malignancies - Hodgkin's disease, leukaemia, carcinoma
Other - Amyloidosis, multiple myeloma, systemic lupus
erythematosus, anaphylactoid purpura
12.
capillary permeability, the idea of stimulating adrenal cortical
activity with corticotrophin or of administering the
adrenocorticoids themselves emerged. Many workers in the early
1950's demonstrated that in many of these patients the
administration of corticotrophin induced remission. Thorn,
Merrill and colleagues (1950) and Barnett, McNamara and
colleagues (1950) found the same with cortisone. These results
were soon confirmed by other workers. Presently treatment with
prednisone is preferred. Although the alternate-day regime
is widely recommended, Diethelm et 
al(11) 
have found that while
this regime reduced the untoward side effects of corticosteroids
in the recipients of renal allografts, the risk of precipitating
allograft rejection became a significant threat. The subjective
experience at the Renal Clinic, King Edward VIII Hospital
(H.M. Coovadia, personal communication) is that alternate-day
administration of prednisone did not produce the desired
clinical response in Indian children with minimal change
nephrotic syndrome. Prednisone was therefore administered on a
daily basis. It is therefore imperative to establish the
subsequent effect of steroid therapy on growth suppression -
which is not only one of the more important but also an
insiduous adverse effect and therefore less easily and quickly
perceived.
2. PATIENTS AND METHODS
The patients were chosen if they:-
i. had nephrotic syndrome, the diagnostic criteria of which
are oedema, hypoalbuminaemia (<30 Gm/1) and heavy
proteinuria (>2 Gm/M
2
/24 hrs or 3 Gm/1 on repeated
random samples).
ii. had sufficient data with respect to therapy, clinical
course and height measurements, and
iii. did not have any chronic illness other than nephrosis
which might have affected their growth.
13.
Thus only 125 of 478 patient records available at the Renal Clinic,
King Edward VIII Hospital, Durban were suitable for this retrospective
study.
Steroid therapy was administered once daily as follows : prednisone
2 mg/kg/24 hrs for four weeks, this dosage being gradually decreased
over the following eight weeks. Most of the children i.e. 61 of 87
children received repeated courses of corticosteroids. The duration
of therapy was obtained by calculating the number of weeks during
which the patient was taking prednisone. Those children who did not
receive steroids were treated symptomatically with diuretics
(thiazides, spiroholactone) or intravenous infusion of salt free
albumin together with an intravenous injection of furosemide during
severe relapses. The children were followed up from three months
to fourteen years, the mean follow up period being 3,9 years.
Heights were measured with the child standing barefooted against a
vertical wall; with both the heels and occiput touching the wall.
A square rule was used to maintain the vertex at right angles to the
wall and thereby accurately localising the upper limit of height which
was read off a measuring scale attached to the wall. The last
recorded height was chosen, which was an average of 77,1 weeks after
completion of steroid therapy (range :from 1 week of being put onto
prednisone to 364 weeks of having completed therapy). Height of
boys and girls at different ages were compared by calculating the





where x is the measured height, x the mean height and S
x 
the
standard deviation. The figures for x and S x were taken from tables
(27)
compiled by the National Center for Health Statistics (NCHS)
14.
Once the mean height SDS was known, the mean height percentile was
determined as follows: S
x 
and x were obtained from the respective NCHS
tables and height x was obtained by substitution of these values in the
equation. This height was then plotted on the respective NCHS
Growth Curves and the percentile extrapolated (See Addendum, p. 36).
The histological classification of nephrotic syndrome adopted by the
clinic was based on the one suggested by Morel-Maroger (1976)(24) 
-
see Table VI.
In addition to comparing the height of all the children who received
steroid therapy (.treatment group) with the heights of those who did
not receive this treatment (control group), an analysis of the height
differences between the two races and the sexes, on treatment, was
also done. Analysis was undertaken using a non-parametric statiscal,
The Mann-Whitney U Test. A significance level of 5% was used. No
comparison was made between the histological subtypes of nephrotic
syndrome, because other than minimal change nephrotic syndrome, the
numbers were too small.
3. RESULTS
3.1 Race, Age, Sex, Histology 
There was a total of 83 Indian patients (51 males) and 42
African patients (25 males). Their ages ranged from 1 to 12
years, the mean age of the Indian children was 4,8 years,
whilst that of the African children was 7 years. One hundred
and seven children had renal biopsies performed on them. The
subsequent histological classification was done according to
the system suggested by Morel-Maroger (1976)
(24)
 . The
distribution of the different histological sub-types of
nephrotic system in both African and Indian children is shown
in Table VII. Eighteen of the 37 African children who had
undergone renal biopsies i.e. 49% had membranous glomerulo-
nephropathy while 57 of the 70 Indian children, i.e. 81% who
15.
















Table VII. The Incidence Of The Histological Sub-types Of Nephrotic
Syndrome In The Different Races and Sexes.
The Sub-type
Africans Indians
M F T M F T
Minimal
Change
3 4 7 35 22 57
Membranous
Glomerulonephropathy
14 4 18 0 0 0
Proliferative
Glomerulonephritis
4 5 9 2 2 4
Membrano-proliferative
Glomerulonephritis
1 0 1 1 1 2
Focal proliferative
Glomerulonephritis
0 2 2 2 2 4
Focal
Glomerulosclerosis
0 0 0 2 1 3
Not
Biopsied
3 2 5 9 4 13





had undergone renal biopsies had minimal change nephrotic
syndrome. Of the 5 African children who were not biopsied
one was steroid sensitive, and 12 of the 13 Indian children
who were not biopsied were steroid sensitive. These proportions
reflect the overall picture of nephrotic syndrome among African
and Indian children in Natal, South Africa (Coovadia et al) 
(9)
.
They reported that the majority of African children (86%) had
obvious structural glomerular lesions which were associated
with unresponsiveness to steroid therapy, while 75% of the
Indian children had minimal change nephrotic syndrome which
was steroid responsive.
3.2 Height Attainment in Indian Children 
Fifty-seven of the 83 Indian patients had received repeated
courses of prednisone while 20 received one course. The
distribution of the height SDS's of both the treatment and
the control groups is shown in Figures 2(a) and 2(b). The
mean height SDS's of the treatment and control groups are
-1,06 (between the 10th and 25th percentile) and -0,92
(between the 10th and 25th percentile) respectively. On the
basis of the Mann-Whitney U Test, there was no significant
difference in height between the two groups (p = 0,75). These
results together with their standard deviations are shown in
Table VIII.
3.3 Height Attainment in African Children 
Four of the 42 African children received repeated courses of
prednisone while 6 received one course. The distribution of
the height SDS's of both the treatment and the control groups
is shown in Figure 3(a) and 3(b). The mean height SDS's of
the treatment and control groups are -1,82 (just below the
5th percentile) and -1,77 (between the 5th and 10th percentile)
respectively. On the basis of the Mann-Whitney U Test, there
was no significant difference in height between the two groups
(p = 0,74). These results, together with their standard
deviations are shown in Table IX (See Addendum, p. 38).
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Control 6 -0,92 0,96
•





































n • 0 
U
n • 00




• n n • • n • I. .111 icu—I .-1







ti) o Ln o Ln 0 u o in
0 , . .. . ... .


























N N 4"•1 m m
I I I 1













Treatment 10 -1,82 0,81
0,74
Control 32 -1,77 1,61
22.
3.4 Race
Since African nephrotic children differ from Indian nephrotic
children with respect to histological type, response to
treatment, etc., the results were further analysed to determine
if prednisone affected their heights differently. The results
are shown in Table X. Mean height SDS of Indian children was
-1,06 (between 10th and 25th percentile) whilst that of the
African children was -1,82 (just below the 5th percentile).
There is no significant difference in height between Indian
and African children treated with steroids (p = 0,08).
Since the effects of corticosteroid therapy on linear growth
is similar for both races, the following analyses were made
irrespective of race.
3.5 Sex
Males on treatment were compared with females on treatment to
determine whether prednisone affected the height of one sex more
than the other. The 52 males on prednisone had a mean height
SDS of -1,24, equivalent to a height between the 5th and 10th
percentile, whilst the 35 females had a mean height SDS of
-1,53 equivalent to the 5th NCHS percentile (Table XI). There
is no significant difference in height between the sexes.
3.6 Duration of Steroid Therapy 
Sixty-four of the 87 children who received prednisone, recei -:ed
the drug for less than 36 weeks, whilst 23 were on treatment for
more than 36 weeks. This period of 36 weeks was chosen as it
was the mean duration of steroid therapy. In addition, Lam
(20)
states that the chances of catch up growth decreases when
children receive prednisone therapy for longer than 6 months.
The statistical analysis of these two groups is shown in
Table XII. No significant difference in height between the two
groups is evident (p = 0,68).
23.
Table X. Height Comparison Between Group A : Indian Children on









A 77 -1,06 1,44
0,08
B 10 -1,82 0,81
24.
Table XI. Height Comparison Between Group A : Males On Steroids









A 52 -1,24 1,21
0,98
B 35 -1,53 1,06
25.
Table XII. Height Analysis. Group A : Children Who Received
Steroids For Less Than 36 Weeks. Group B : Children









A 64 -1,09 1,41
0,68
B 23 -1,23 1,48
26.
4. DISCUSSION 
It is evident from this study that both Indian and African children
with nephrotic syndrome on repeated courses of daily, high-dose
prednisone continue to grow normally. Growth suppression is documented
as one of the most common adverse effect of corticosteroid therapy
with children who receive repeated courses of high-dose steroids or
prolonged maintenance therapy being at the greatest risk
(20)
 . The
most important recommendation to reduce the adverse effects of
corticosteroid therapy is alternate-day therapy rather than a daily
regime. However, children at the Renal Clinic were put onto daily
treatment because of the experience that alternate-day treatment was
not accompanied by a good clinical response of the disease in Indian
children. Despite this regime no growth retarding effects were noted.
The NCHS reference population, which is representative of healthy
American children was used to compare the linear growth of these
children. It is appropriate to use these NCHS standards for
comparison because, as Graitcer and Gentry, 1981 found, child
growth is mainly influenced by socio-economic status and not by
(19)
race or by ethnicity . Also, as has been shown by Coovadia et
al, 1978 the length measurements of Negro children less than 2 years
of age in the Durban area are similar to the Harvard standards,
whereas older children are considerably shorter, their mean height
lying between the 5th and 10th Harvard percentiles
(10)
 . This
decrease in height (and weight) probably reflects the damaging effects
of an impoverished socio-economic environment on growth.
The findings of Cherian et al
(7)
, in their study of children in
Zaria, Nigeria, are very similar. Furthermore, studies of Indian
children 
(2)




 in his study on growth of middle and upper class Indian
school children in Durban confirms that their growth parallels that
of American children and therefore one is justified in using the NCHS
standards for the local population.
The height SDS's of the treatment and control groups are representative
of all the nephrotic patients seen at King Edward VIII Hospital,
27.
and not just a selected group with an altered sensitivity to steroid
therapy. The mean height SDS of all the children was -1,38 equivalent
to a height on the 5th percentile (NCHS).
Seventy-seven of the 83 Indian nephrotic children i.e. 92,8% received
steroid therapy whereas only 10 of the 42 Africans i.e. 23,8% received
steroids. The mean height SDS of the treatment group of Indian
children was -1,06 equivalent to the 10th percentile (NCHS) and that
of the control group was -0,92, equivalent to a height between the
10th and 25th percentile. There is no significant difference in
height between these two groups (p = 0,75). Similarly, no significant
difference was found when comparing the treatment and control
groups of African children (p = 0,74). The mean height SDS of those
who had been on prednisone was -1,82 (just below the 5th percentile)
whilst the mean height SDS of those who had not been on steroids was
-1,77 (between the 5th and 10th percentiles). These are close to the
observed heights of average urban Negro children in Durban
(10)
Thus corticosteroid therapy in children with nephrotic syndrome does
not affect their height.
The data compiled were further analysed to determine whether
prednisone might have had any growth inhibiting effects which were
variable with race. When comparing the 6 Indian children from the
control group with the 32 African children from the same group, no
significant difference in height (p = 0,20) is evident (see Table xIII).
This is not unexpected since, as has been mentioned above, child
growth is not affected by race. Also, the height of these children
are normally distributed (Fig. 2 and 3) implying a similar socio-
economic status. Similarly a comparison between the 77 Indian
children and the 10 African children within the treatment group
reveals no significant difference in height (p = 0,08)---Table X.
Since there is no significant difference in height between the Indian
and African nephrotic children from both the control and treatment
group, it can be concluded that the effects of prednisone on height
do not vary with race.
Foote et al
(16) 
showed in their study of 80 patients with steroid
responsive nephrotic syndrome that growth was suppressed during
28.
Table XIII. Height Analysis Between Group A : Indian Children Not










A 6 -0,92 0,95
0,20
B 32 -1,77 1,60
29.
corticosteroid therapy, but their ultimate height attainment was not
significantly affected. However, they do also indicate that their
patients were a "selected group whose nephrotic syndrome was, on
average, much more severe than would be encountered in a non-
specialist unit. Thus, most received large doses and long courses
of prednisone ...".
Travis et al(34) stated that "In children treated with steroids for
glomerulonephritis or nephrotic syndrome and especially in children
with renal transplantation, factors other than steroid therapy may
contribute to growth retardation". The specific disorders in kidney




ii. impaired conservation of water
iii. osteodystrophy
iv. endocrine factors: the role of endocrine in the growth
retardation of renal disease is unclear. Growth
hormone levels are normal or increased in children with
renal failure. Somatomedin has been reported to be low
in growth retarded children with renal insufficiency.
v. abnormalities of protein metabolism and decreased food
intake.
One can therefore argue that in the study by Foote et al that the
stunting of growth which occurred during steroid therapy might have
been the result of the severity of the disease, or of a combination
of both these factors.
Although Indian and African children behave similarly with respeo-:
to growth and prednisone therapy, this study does confirm the
contrasting clinicopathological patterns of nephrotic syndrome
these two South African races. Coovadia et al
(9)
 showed that 8d;
of African children with nephrotic syndrome had obvious structural
glomerular lesions which were associated with unresponsiveness to
steroid therapy in contrast with the 75% of the Indians who had
minimal change nephrotic syndrome which was steroid responsive.
Extramembranous and proliferative lesions accounted for most of the
30.
histological types of nephrotic syndrome in African children. In
the present study 30 of the 37 African children, i.e. 81%, whose
histology was confirmed had obvious structural glomerular lesions
(membranous glomerulonephropathy--49%) whilst 57 of the 70 Indian
children i.e. 81% had minimal change nephrotic syndrome. Of the 5
African children who were not biopsied, only 1 was steroid responsive,
whilst 12 of the 13 Indian children who were not biopsied were
steroid responsive.
It has been reported that catch-up growth may occur after cessation
of daily steroid therapy but that this was not always the case
especially when therapy had been prolonged for more than 6 months
(20)
An investigation was therefore done to ascertain whether the height
of children was affected by duration of prednisone therapy. The
children in this study received steroids for a period of 4 to 250
weeks, the mean period being 35,9 weeks. When comparing children
who received prednisone for less than 36 weeks with those who
received treatment for longer than 36 weeks one finds no significant
difference (p = 0,68) in height (Table XII). The mean height SDS
of these groups were -1,09 and -1,23 respectively, both being between
the 10th and 25th percentile (NCHS). Thus there was no correlation
between duration of prednisone therapy and height. This confirms
the findings of Foote et 
al(16) 
that there was no correlation
between total prednisone dose and ultimate height attainment
(See Addendum, p. 38).
The 52 males on prednisone had a mean height SDS of -1,24,
equivalent to a height between the 5th and 10th percentile whilst
the 35 females had a mean height SDS of -1,53, equivalent to the
5th NCHS percentile (Table XI). Using the Mann-Whitney U Test, no
significant difference in height between males and females on
steroids is evident (p = 0,98). Thus the effects of prednisone
were not altered by the sex of the individual.
Other than the minimal change nephrotic syndrome, the numbers of
each of the other histological types of nephrotic syndrome were
too small for any further statistical analysis.
31.
5. CONCLUSION
Although it is widely accepted that prolonged corticosteroid therapy
adversely affects the growth of young children, this study of 125
nephrotic children clearly demonstrates that prednisone therapy did
not inhibit linear growth. Furthermore, neither the duration of
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1. Determination of mean height percentile if mean height SDS is
known (Refer to p. 14) :-
i. Given:
Mean height SDS = -1,06
ii. Select S and x from NCHS tables for any age and sex:-
For a 7,5 yr. old male
S = 5.,2 cm
x = 124,5 cm
iii. Substitute these values in equation (Refer to p. 13):-
SDS =
Sx
x = 119 cm
iv. Read off the percentiles from the respective percentile charts.
Height SDS of -1,06 = a height between the 10th and 25th
percentile.
2. Two additional analyses were performed:-
i. Patients that received less than twelve weeks of Prednisone
were excluded from the study since it is unlikely that
short courses of steroids inhibit growth; and the inclusion
of these patients might have prejudiced the results. Seventeen
Indians and three Africans were subsequently excluded and the
results are shown in Table XIV.
X - X
Table XIV. Height analysis after exclusion of children who received









Indian Treatment 60 -0,98 1,48
0,87





Control 32 -1,77 1,60
37,
38.
There is no significant difference in height between the
treatment and control groups in both Indian and African
patients (p = 0,87 and 0,88 respectively).
ii. A regression analysis - as illustrated in Figure 4 - was
done to determine whether duration of prednisone therapy
affected growth.
Although there appears to be a tendency towards growth
inhibition with increasing duration of prednisone therapy,





Regression Slope = -0,0023 + 0,0033
Y - intercept = -1,04 + 0,15
P > 0,05
Thus, duration of prednisone therapy did not affect growth.
3. i. The small sizes of the Indian control and African treatment
groups were unavoidable since it would be unethical to , alter
treatment for the purposes of this study. The non-parametric
Mann-Whitney U Test was therefore chosen as it allows for
comparisons between groups with distribution of samples free
of any specific pattern.
ii. Two African children in the control group (SDS = -4,7 and
-6,7) were short at the onset of their disease (SDS = -4,6
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Figure 4. Height SDS versus Duration of Prednisone Therapy.
• : Indian Children
• : African Children
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iii. Growth charts for average Indian children in Durban are
unavailable. However, the majority of these children
are malnourished, (pers. comm. Professor H.M. Coovadia,
Department of Paediatrics and Child Health, University
of Natal) and it is therefore not surprising that they
are shorter than Moosa's select study group of upper
and middle class children.
iv. The conclusions of this study are applicable to the
groups as a whole and not necessarily to individuals.
Growth inhibition could have occurred in a few children
but because the Indian control and African treatment
groups were so small, the effects could have been masked.
